Boehringer Ingelheim≤& and Inflammasome Therap♦↓÷eutics Inc. (Inflammasome) today announ♥<✘ced they have entered i‍ nto a co-development and license agr∑♣←eement to develop up to three therapies f≥♠or patients with retinal diseases. By combining∞​ Inflammasome’s unique intravitreal (IVT) drug d≠♦‍elivery technologies with Boehringer Ingelhei‍‍★m’s compounds from its retinal diseas∑↓e pipeline portfolio, Boehringer Ingel‌"heim aims to develop✔★ novel therapies for retinal d"→λδiseases.In 2019 there were an estimate'←☆₹d 82 million patients in the seven ke∞✘φy countries (U.S., Japan, German♠​α♥y, U.K., Spain, Italy, France) affected by one '↓of the three major forms o✔<≠f retinal disease: Age related <γmacular degeneration (AMD), diabetic retinopath"↕↕y (DR), and diabetic macular edema (♦® 'DME). Globally, the prevalence rates of these and₩ ∏  other retinal diseases are expected to increas↑ε™e over the next 10 years primarily du©₩© e to aging populations and the global♥∞∏ diabetes epidemic. Despite therapeutic adva•£§ nces in some disease areas during the pas♥σφ♦t years, the real world results are poo ↔±r, and there are no or only₩₹♥ limited treatment options in many areas, r€←esulting in an overall high ↓₽↓unmet need. The collaborat₽♥×ion between Boehring'↔er Ingelheim and Inflammasome aims to address tλ$δγhis challenge by using InflammasΩ≥§ ome’s technology to deliver therape φutics in a biodegradable>≥ gel formulation into the eye.“We are delighted  ∑to enter into a collabora× ±tion with a company of Boehringer Ingelheim ¶λ’s stature,” said Paul Ashton, Chi•≈€ef Executive Officer of Inflammasome $→Therapeutics. “We look ×αforward to working with their t§‌eam to leverage our respective technologies and≥β expertise to develop new therapies for  §™devastating retinal diseases≥" leading to blindness. This collaboration fits<β↔∑ our strategy of advancing the company λ÷£via both collaborations and internal de©‌βvelopment.”“Boehringer Ingelheim is looking for<‌ward to developing Inflammasome’s n"→'πovel technology for th£ ‌&e delivery of our first-in- class retinal d £₽isease compounds working jointly with Inflammasom↓≠→™e’s highly experienced scientific team,” ">said Clive R. Wood, PhD, Senior C₽  §orporate Vice President, Di§Ω₽scovery Research at Boehringer Ingelhei≈α$∏m. “This will enable us ✔'Ωto develop a broad range of novel therapy option♠£s for the many patients with re✔←¥×tinal diseases waiti→>♠&ng urgently for better≥&©≈ and new therapy optφ§εions.”Boehringer Ingelheim ta∞σ kes a holistic approach in the development of nov♥™​el retinal disease therapies, targeting key m±↕≥≤echanisms in the pathogenesis of retinal disease®✔↔s. The company has built a comp"≈¥rehensive pipeline po×‍←≤rtfolio of next generation∑" therapy approaches in various stages of deσλ>velopment up to Phaseδ '® 2 in macular degeneration, d♥"αiabetic retinal diseases and beyond. Infl®♠ammasome’s novel delivery technology using a long$Ω★-acting degradable IVT implant complements tφ↓€his portfolio.Inflammasome is entitl®÷βed to receive up to $160 milli$φ→∞on in up-front, research and development sup± γ port and milestone gated developme★λnt payments as well as tiered royalties based on→©$$ future commercial sales of developed products an ≥♥©d other milestones due on commercialization.infβ ©ormation source:pharma✘₽±≈ focus AsiaThe original link:ht↓✘tps://www.pharmafocusasia.com/news/boe↑"hringer-ingelheim-partners-with-inflam≥←±≈masome-therapeutics-to-develop->φ±novel-therapies-for-patients-with-retin∏γal-diseases2019 Asia-pacific pharma IP Leader S≈≥® ummit: http://en.zenseegroup.com/p/₹≤510934/will be held in Beiji♣↓ng  on November 1α∏÷4-15, and will attract more th£☆‌an 500 industry experts from domestic andφ↕"♥ foreign pharmaceutical companies, biotechnoπ₽γlogy companies, governments, associations, law fi↓≤rms, intellectual property agents and other cγ¶ompanies to attend.Off​₽δ→icial registration and consultatio"→ ₹n channels:Contact：AnnPhone: 021-656 σ₩₹50305Email：Marketing@zenseegroup.comhttp://ww₽β>±w.zenseegroup.com/forms/view/22113/

Clene Nanomedicine, ♦✘Inc., a clinical-stage biopharmaceutical com÷​pany, announced today that the Sean M. Heal₹♠φ✔ey & AMG Center for ALS at Mass General h ↕as selected CNM-Au8 for inclusion in the first ev♥倶er Platform Trial for the treatment of amyotrop®‌εhic lateral sclerosis (ALS).The♥  Healey Center issued a call earlier this yeaα÷£r for the best therapeutic¶&σ÷ candidates to apply for entry in←₽ to the HEALEY ALS Platform Trial. They received∞γπ responses from nearly 30 applicants a✔φcross ten countries. Members from the Healey Cent&¶≠er Science Advisory Committee, a₩α♥ group of renowned ALS scientiαΩsts, chose the top five therapeutσ♣ic candidates, including Clene's lead clinical a↕∞ε↕sset, CNM-Au8. The se&→ ±lection of CNM-Au8 into theσ→ Healey ALS Platform Trial incl☆&≤₩udes substantial financial support and provide↓→s access to over 50 e ≠xpert ALS clinical tri♦↑‌&al sites across the Unit↔$©ed States."Our goal," said Merit Cudko♣•​wicz, MD, MSc, Director of the Healey Cen$'ter, "is to lower the barriers for§σ×∑ our pharma and academic colleagues to bring thei✘¶↑r exciting therapies for ALS forward to clinical ≤≥∞×trials. We are determined to acceleratπ≠♣®e therapy development for ALS."Import★♦♠✘ant preclinical work supporting♠ε®& the effort with CNM-Au8 was per• γformed in the laborat≤≤↕ory of Nicholas J. Mara✔±→σgakis, Director of the ≈←ALS Center for Cell Therapy and Reg∞☆≥eneration Research at Johns Hopkins, δ≈using human induced pluripo ∑≤®tent stem cells from₽  ALS patients. Dr. Maragakis is Chair of Cl±∏☆εene's Scientific Advisory Board for ALS.Dr. Jonat≤​han Glass, Professor of Neurology andπ​≤≈ Pathology at Emory University School of Medi​↔§<cine, as well as Director of the Emory ALS ♦ Center, remarked, "CNM-Au8 is quite an interes£$←ting compound that is ready for test☆γ↑'ing in ALS clinical trials.  Its inclusion i§∑≠n the Platform Trial initiative is ☆≠✘an excellent way to move forward for the develop<​ment of CNM-Au8 as aδ' potential therapeutic for ALS.""We are ve₽€ry pleased Clene's CNM-Au8 has been selected fo←γ ↓r participation in t✘≤he Healey ALS Platform Trial. We believe the uΩ£™nique mechanism of CNM≈‍©ε-Au8 represents a prom$¥"∏ising new approach for the treatmentφ♦±↔ of neurodegenerative diseases, includi‍♥γ$ng ALS, with the potential for meaningful imp₩&±•act for the community of people diagno↔✘↓sed with this devastating and d♠$ebilitating disease," said Rob Ether★‍₹§ington, President and ®>≥CEO of Clene. "We are continuing  ↓Ω™the development of CNM-Au8 in several clinical s± tudies set to launch later this≥§ year."2019 Asia-pacific pharma IP Leader ★↓$Summit: http://en.zenseegroup.com≠¥'Ω/p/510934/will be held in ¥¶ε₽;Beijing  on ✘βΩ November 14-15, and ≥÷will attract more tha® δn 500 industry experts from dom↓≈estic and foreign pharmaπ∏λ♣ceutical companies, biotechnoloπ≠gy companies, governments, assoc>↔εiations, law firms, in↓₽tellectual property agents and other companies✘→ε to attend.Official registration and consultation♦ ✘© channels:Contact：AnnPhone: 021-65650305Email：Marα↓←keting@zenseegroup.comhttp://www.zense₹©δegroup.com/forms/view/22113/

iBio, Inc. today announced that it has ent​ ered into the initial©♥¶ Statement of Work (“SOW1”)≈φ✘₹ under its Memorandum→γ of Understanding (“MOU”) with AzarG₽₹↕en Biotechnologies (Pt™α¶y.) Ltd. (“AzarGen”).Following iBio’s successf×​✔♠ul use of its technologies and manufa₽±εcturing capabilities$σ≈" to advance the development ←ε¶≠of AzarGen’s surfactant protein therapeutic thr>¥ough an initial assessment of production™₹≠ feasibility, in May 2017, the ​÷​ two companies expanded their collaboration by iniλβε•tiating the development of a plant-made rituxima✔®∞b for the South African m₹§arket under the MOU.Puβ‍≥rsuant to the SOW1, iB←☆ε‍io will manufacture r↑♥esearch quantities of σ‌ a plant-made rituxi"₩$♣mab for AzarGen using iBio’s proprietar ®y FastPharming™ System. Followi♦¥ng batch production, the dru∞•γg product candidate will¥✔ undergo testing via iBio CDMO’s bioanalytical s™↔★ervices.“After demonstrating the success of our ♥ platform through our ope®‍ning project with AzarGen, we♥∑ are now advancing to the next s£π₹tage of the two companies♠¥’ collaboration,” commented Robert •≠↔B. Kay, iBio’s Chairman ♠©☆•and CEO. “We look forward to‍¶☆₩ helping AzarGen develop a plant-based, bio-sim &® ilar rituximab product foβ≈r the South African market.”“The early success in∑‌ combining iBio’s and∑£∏& AzarGen's advanced genetic engine♠±€ering and synthetic biologλ‍↕y techniques in plants really e✘♥mpowered us to evolve our bα€usiness plans and product priori♦€ties to initiate development of a biosimilar ver↕✘≥sion of rituximab,” said Dr. Mauritz V∑•enter, CEO of AzarGen. “As we continue to move ★☆₽toward the initiation of advanced pre-clinical ac↕✘σ₩tivities, we are confident that iBio CDMO is i®λdeally suited to provide >★&us with the requisite long-$<¶∞term process development and×↕λ↔ cGMP manufacturing support. We are excit≠→♦ed to take this impor ★↓≥tant step forward in advancing th×☆≥is program. Focusing on accessibility and affo♣∑ ∞rdability of biological medicine for the African​✔εΩ continent, we look forward to initiatin  g additional project¶≤↑•s with iBio as we progres β®s.”Rituximab was first approved by thΩ×βe U.S. Food and Drug Administration inφγγ  1997 for treatment of certain B ∏≤cell non-Hodgkin lymphomas. Si‍♦nce that time, its clinical uses ha₽€₽Ωve expanded to encompass tre✘β≥atment of chronic lymphocytic le≈±¥ukemia, as well as a range of autoim±" mune diseases, including certain types of rheuma≈÷toid arthritis. Rituximab has been placed on♦♠ the World Health Organ'   ization’s List of Essential '±Medicines and it was ranked as one of Ω™ the world’s top-10 sellinΩ♠g pharmaceuticals in 2018.2019 Asia-pacif♦♠ic pharma IP Leader Summit: http://en.zeε∑nseegroup.com/p/404716/ will be h✔←∑‍eld in Beijing  on&✔÷•¶nbsp;November 14-15, and wil•×l attract more than 500 industry experts from dom→♦©©estic and foreign pharmaceuti♣¥cal companies, biotechnolog™★₹<y companies, governments, associ↔​ ations, law firms, intellectual property age§δnts and other companieγ§s to attend.Official registration and co∑>≥nsultation channels:Contact：AnnPhone: 021-656503←λ≠≤05Email：Marketing@zenseegroup.comhttp:↓ <δ/forms/view/22113/'¶γ↓